Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment

@article{Moon2010PredictiveVO,
  title={Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment},
  author={Joon Ho Moon and Shi nae Kim and Byung Woog Kang and Yee Soo Chae and Jong Gwang Kim and Jin Ho Baek and Jae Hoo Park and Moo Kon Song and Joo Seop Chung and Jong-ho Won and Sang Min Lee and Young Don Joo and Yeo Kyeoung Kim and Hyeong Joon Kim and Deog Yeon Jo and Sang Kyun Sohn},
  journal={Annals of Hematology},
  year={2010},
  volume={89},
  pages={681-689}
}
This study analyzed the outcomes of myelodysplastic syndrome patients treated with azacitidine. Between August 2006 and June 2008, a total of 126 patients were treated with azacitidine at a dose of 75 mg/m2/day subcutaneously for 7 days, which was repeated every 28 days. The median age of the patients was 64 (range, 20–82) years. Forty-three patients (33.4%) were classified as intermediate-2 and high risk according to International Prognostic Scoring System (IPSS), while 61 patients (47.3… CONTINUE READING